Product Description: 306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies[1][2].
Applications: Cancer-programmed cell death
Formula: C75H151N7O4S8
References: [1]Qiu M, et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):e2116271119./[2]Yuan Z, et al. Impact of physicochemical properties on biological effects of lipid nanoparticles: Are they completely safe. Sci Total Environ. 2024 Jun 1;927:172240.
CAS Number: 2803699-70-7
Molecular Weight: 1471.57
Compound Purity: 99.27
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)/Ethanol : 25 mg/mL (ultrasonic)
Target: Liposome
English
Deutsch
